These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 36064828)

  • 21. Outcomes of Children with Inflammatory Bowel Disease who Develop Anti-tumour Necrosis Factor-induced Skin Reactions.
    Dolinger MT; Rolfes P; Spencer E; Stoffels G; Dunkin D; Dubinsky MC
    J Crohns Colitis; 2022 Sep; 16(9):1420-1427. PubMed ID: 35390140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Analysis of a case series of adult patients with severe atopic dermatitis treated with dupilumab in Argentina].
    Máspero J; Angles MV; Ardusso L; Brancciforte M; Castro C; Cruz Iturrieta C; Chouela E; De Gennaro MS; Fernández Bussy R; Galimberti ML; Galimberti RL; Gattolin G; Luna PC; Magariños G; Marini MG; Maskin M; Plafnik R; Raimondo N; Russo JP; Sevinsky L; Stringa MF
    Rev Fac Cien Med Univ Nac Cordoba; 2020 Jun; 77(2):94-99. PubMed ID: 32558511
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term real-world experience of the side effects of dupilumab in 128 patients with atopic dermatitis and related conditions aged 6 years and above: Retrospective chart analysis from a single tertiary care center.
    Parmar NV; Abdula MA; Al Falasi A; Krishna CV
    Dermatol Ther; 2022 May; 35(5):e15415. PubMed ID: 35238115
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ustekinumab and vedolizumab for extraintestinal manifestations in inflammatory bowel disease - a retrospective study.
    Livne-Margolin M; Ling D; Attia-Konyo S; Abitbol CM; Haj-Natour O; Ungar B; Ben-Horin S; Kopylov U
    Dig Liver Dis; 2023 Feb; 55(2):223-229. PubMed ID: 36241535
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ustekinumab for skin reactions associated with anti-tumor necrosis factor-α agents in patients with inflammatory bowel diseases: A single-center retrospective study.
    Ezzedine K; Visseaux L; Cadiot G; Brixi H; Bernard P; Reguiai Z
    J Dermatol; 2019 Apr; 46(4):322-327. PubMed ID: 30816581
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of dupilumab-associated ocular surface diseases in atopic dermatitis patients.
    Guex-Crosier Y; Di-Lucca J; Häusermann P; Laffitte E; Saulite I; Schmid-Grendelmeier P; Schürch K; Thormann K; Simon D
    Swiss Med Wkly; 2021 Aug; 151():w30020. PubMed ID: 34495603
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.
    Paller AS; Bansal A; Simpson EL; Boguniewicz M; Blauvelt A; Siegfried EC; Guttman-Yassky E; Hultsch T; Chen Z; Mina-Osorio P; Lu Y; Rossi AB; He X; Kamal M; Graham NMH; Pirozzi G; Ruddy M; Eckert L; Gadkari A
    Am J Clin Dermatol; 2020 Feb; 21(1):119-131. PubMed ID: 31823222
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dupilumab for treatment of atopic dermatitis.
    Seegräber M; Srour J; Walter A; Knop M; Wollenberg A
    Expert Rev Clin Pharmacol; 2018 May; 11(5):467-474. PubMed ID: 29557246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.
    Papamichael K; Cheifetz AS; Melmed GY; Irving PM; Vande Casteele N; Kozuch PL; Raffals LE; Baidoo L; Bressler B; Devlin SM; Jones J; Kaplan GG; Sparrow MP; Velayos FS; Ullman T; Siegel CA
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1655-1668.e3. PubMed ID: 30928454
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial.
    Paller AS; Simpson EL; Siegfried EC; Cork MJ; Wollenberg A; Arkwright PD; Soong W; Gonzalez ME; Schneider LC; Sidbury R; Lockshin B; Meltzer S; Wang Z; Mannent LP; Amin N; Sun Y; Laws E; Akinlade B; Dillon M; Kosloski MP; Kamal MA; Dubost-Brama A; Patel N; Weinreich DM; Yancopoulos GD; O'Malley JT; Bansal A;
    Lancet; 2022 Sep; 400(10356):908-919. PubMed ID: 36116481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mesenchymal Stem Cells Profile in Adult Atopic Dermatitis and Effect of IL4-IL13 Inflammatory Pathway Inhibition In Vivo: Prospective Case-Control Study.
    Campanati A; Orciani M; Marani A; Di Vincenzo M; Magi S; Gregoriou S; Diotallevi F; Martina E; Radi G; Offidani A
    J Clin Med; 2022 Aug; 11(16):. PubMed ID: 36013001
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic Evaluation of Dupilumab for Moderate-to-Severe Atopic Dermatitis: A Cost-Utility Analysis.
    Zimmermann M; Rind D; Chapman R; Kumar V; Kahn S; Carlson J
    J Drugs Dermatol; 2018 Jul; 17(7):750-756. PubMed ID: 30005097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment persistence of ustekinumab and vedolizumab in IBD patients is independent of prior immunogenicity to anti-TNFs: a retrospective study.
    Blesl A; Petritsch W; Binder L; Fürst S; Wenzl H; Baumann-Durchschein F; Kump P; Högenauer C
    Scand J Gastroenterol; 2022 Nov; 57(11):1327-1330. PubMed ID: 35732583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is dupilumab effective in adult-onset atopic dermatitis: Real-life experience of 16 patients.
    Erbağcı E; Demirel Öğüt N; Koç Yıldırım S; Hapa FA
    J Cosmet Dermatol; 2022 Oct; 21(10):4852-4857. PubMed ID: 35100490
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.
    Beck LA; Thaçi D; Hamilton JD; Graham NM; Bieber T; Rocklin R; Ming JE; Ren H; Kao R; Simpson E; Ardeleanu M; Weinstein SP; Pirozzi G; Guttman-Yassky E; Suárez-Fariñas M; Hager MD; Stahl N; Yancopoulos GD; Radin AR
    N Engl J Med; 2014 Jul; 371(2):130-9. PubMed ID: 25006719
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of inadequate response and adverse effects to dupilumab in atopic dermatitis.
    Narla S; Silverberg JI; Simpson EL
    J Am Acad Dermatol; 2022 Mar; 86(3):628-636. PubMed ID: 34126094
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial.
    Worm M; Simpson EL; Thaçi D; Bissonnette R; Lacour JP; Beissert S; Kawashima M; Ferrándiz C; Smith CH; Beck LA; Chan KC; Chen Z; Akinlade B; Hultsch T; Staudinger H; Gadkari A; Eckert L; Davis JD; Rajadhyaksha M; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Ardeleanu M
    JAMA Dermatol; 2020 Feb; 156(2):131-143. PubMed ID: 31876900
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dupilumab dose spacing after initial successful treatment or adverse events in adult patients with atopic dermatitis: A retrospective analysis.
    Patruno C; Potestio L; Fabbrocini G; Napolitano M
    Dermatol Ther; 2022 Dec; 35(12):e15933. PubMed ID: 36227462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Eye Complications During Dupilumab Treatment for Severe Atopic Dermatitis.
    Ivert LU; Wahlgren CF; Ivert L; Lundqvist M; Bradley M
    Acta Derm Venereol; 2019 Apr; 99(4):375-378. PubMed ID: 30653240
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful Combination of Systemic Agents for the Treatment of Atopic Dermatitis Resistant to Dupilumab Therapy.
    Gori N; Chiricozzi A; Malvaso D; D'Urso DF; Caldarola G; De Simone C; Peris K
    Dermatology; 2021; 237(4):535-541. PubMed ID: 33477153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.